Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancer.
Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancer.
复制标题
来自原发性肺癌患者的单克隆抗体对半乳糖基球苷的识别。
DOI：
10.1073/pnas.85.12.4441
复制
发表时间：
1988
影响因子：
11.1
通讯作者：
Old,LJ
中科院分区：
文献类型：
--
作者：
Schrump,DS;Furukawa,K;Yamaguchi,H;Lloyd,KO;Old,LJ
用EB病毒使原发性肺癌患者的淋巴结淋巴细胞永生化，并筛选培养上清液的细胞表面对同种异体癌细胞系的反应性。在初始筛选中含有可检测抗体的威尔斯孔的百分比范围为1%至17%，但绝大多数培养物在随后的扩增中丧失了抗体活性。两个分泌抗体的克隆，J309和D579，来自不同的个人和间变性肺癌细胞系反应，成功地扩大和融合NS-1小鼠骨髓瘤细胞系。由这些克隆产生的抗体对培养的细胞系表现出相同的限制性血清学反应性，并检测到MCF-7乳腺癌细胞的中性糖脂部分中存在的碳水化合物抗原。血清学、免疫化学和化学分析显示，抗体J309和D579识别的抗原是半乳糖基球糖苷[Gal（beta 1-3）GalNAc（beta 1-3）Gal（alpha 1-4）Gal（beta 1-4）- GlcCer]。关于这些发现的意义与肺癌的生物学方面的结论等待进一步的信息，在正常和恶性组织中的分布半乳糖基globoside和这种结构的抗体的频率在正常和荷瘤个体。
Lymph node lymphocytes from patients with primary lung cancer were immortalized with Epstein-Barr virus, and culture supernatants were screened for cell-surface reactivity against allogeneic cancer cell lines. The percentage of wells containing detectable antibodies in initial screening ranged from 1 to 17%, but the vast majority of the cultures lost antibody activity on subsequent expansion. Two antibody-secreting clones, J309 and D579, derived from separate individuals and reactive with anaplastic lung cancer cell lines, were successfully expanded and fused with the NS-1 mouse myeloma cell line. The antibodies produced by these clones exhibited identical restricted serologic reactivity against cultured cell lines and detected a carbohydrate antigen present in the neutral glycolipid fraction of MCF-7 breast cancer cells. Serologic, immunochemical, and chemical analyses revealed that the antigen recognized by antibodies J309 and D579 is galactosylgloboside [Gal(beta 1----3)GalNAc(beta 1----3)Gal(alpha 1----4)Gal(beta 1----4)- GlcCer]. Conclusions regarding the significance of these findings with respect to the biology of lung cancer await further information concerning the distribution of galactosylgloboside in normal and malignant tissues and the frequency of antibodies to this structure in normal and tumor-bearing individuals.